Presentation of Infectious Keratitis to ED during COVID-19 Lockdown

Table 2

Clinical details.

	2020	2019	2018
Admitted N (%)	15 (52)	29 (62)	29 (69)
Treatment N (%)
Cef/Vanc	13 (45)	25 (53)	28 (64)
Ofloxacin	14 (48)	17 (36)	7 (16)
Brolene/PHMB	1 (3)	3 (6)	1 (2)
Anti viral	0	5 (11)	5 (11)
Anti fungal	1 (3)	2 (4)	1 (2)
Not recorded	0	0	3 (7)

Treatment, all patients receiving described treatment, including combination therapy. Cef/Vanc, ceftazidime/vancomycin; PHMB, polyhexamethylene biguanide; others, antifungal and antiviral therapy.